

# Formulation and In Vitro, In Vivo Evaluation Oral Dispersible Tablets of Selgiline

Bandla Indrajya\*<sup>1</sup>, Dr. Khazi Mehraj Abukalam<sup>2</sup>, Gollapudi Rajesh<sup>3</sup>

Research Scholar, Department of Pharmacy<sup>1</sup>

Research Guide, Department of Pharmacy<sup>2</sup>

Shri Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India<sup>1,2</sup>

Research Co- Guide, Department of Pharmaceutics, Max Institute of Pharmaceutical Sciences, Khammam, Telangana<sup>3</sup>

**Abstract:** *Selegiline, a monoamine oxidase (MAO) inhibitor, is FDA-approved as an adjunct treatment in the management of patients with Parkinson disease and as a treatment for a major depressive disorder (MDD) in adults. Selegiline is also used off-label for early Parkinson disease and the treatment of attention-deficit/hyperactivity disorder (ADHD). In this present research work, an attempt was made to develop solid dispersions for the enhancement of solubility, dissolution and bioavailability of Selgiline and also to find the effect of natural super disintegrants in the development of fast disintegrating tablets. Solid dispersions were prepared by solvent evaporation method using PEG 6000 as carrier in different ratios. The optimized solid dispersions were utilized in the formulation of fast disintegrating tablets using different natural super disintegrants in different concentrations. The prepared tablets were evaluated and subjected to in vitro dissolution studies to select the best formulation. All the formulations showed fast disintegrating action. Among all the formulations dehydrated banana powder containing formulations FF5 (96.72) and FF6 (99.27) showed better release rate of Selgiline from the dosage form. Thus, dehydrated banana powder can be utilized as better regular super disintegrant in the advancement of quickly breaking down tablets when compared to orange peel pectin and mango peel pectin. Finally, the optimized formulations were subjected to pharmacokinetic studies in rabbits. The solid dispersion reached peak concentration ( $C_{max}$ ) 11445.46 ng/ml at  $T_{max}$  of 2 h while it was observed to be 9140.84 ng/ml at  $T_{max}$  of 3 h in case of control tablet, indicating that enhancement of absorption in solid dispersion pattern of Selgiline than pure form. The AUC of control and FF6 tablets of Selgiline were 31495.16 and 43126.52 ng-h/ml correspondingly. These results indicated that the FF6 tablet showed enhancement of AUC when compared to control tablet of Selgiline.*

**Keywords:** Selgiline

## I. INTRODUCTION

Oral drug delivery has been known for decades as the most widely utilized route of administration among all the routes that have been explored for the systemic delivery of drugs via various pharmaceutical products of different dosage forms. Oral route remains the preferred route for administration of therapeutic agents because of accurate dosage, low-cost therapy, self-medication, noninvasive method and ease of administration leading to high level of patient compliance. Fast disintegrating tablet (FDT) is "A strong dose structure contains restorative substances, which break down quickly, for the most part inside an issue second, when put up on tongue". FDTs break down as well as disintegrate quickly in spit without the requirement for water.

Super disintegrants are substances which disintegrates the drug within seconds. The major function of disintegrants is to oppose the efficacy of the tablet binder and the physical forces that act under compression to form the tablet. The mechanism by which tablet is broken down into smaller particles and then produces a homogeneous suspension or solution is based on

- i. By capillary action
- ii. High swell ability of disintegrants
- iii. Capillary action and high swell ability

iv. Chemical reaction (release of gases)

## II. MATERIALS AND METHODS

Selgiline drug was gifted by Aurobindo Pharmaceuticals, Hyderabad, Telangana, India. Mango peel pectin, orange peel pectin, Banana powder, PEG6000, Avicel PH 102, Aspartame, Mannitol, Talc, Magnesium stearate from local manufacturers.

### Construction of standard chart of Selgiline

Adjustment bend of Selgiline was plotted in 6.8 pH phosphate support which was chosen from dissolvability study Selgiline was evaluated spectro-photometrically at  $\lambda$  max of 247 nm.

### Solubility investigation of Selgiline

As the pH of the spit (medium present in the oral pit) run from 6 to 7.4, the dissolvability of medication was contemplated in solvents of pH 6.8 phosphate supports and refined water. A 100 mg of medicine was taken and solubilized in 100 ml of solvents autonomously and the dissolvability was watched. Then an appropriate medium was chosen relying on the dissolvability results.

### Compatibility study

Fourier Transform Infrared (FTIR) spectrophotometer was utilized for infrared examination tests to translate association's medication with polymers and different fixings. The spectra of unadulterated medication, bearers and advanced plan were recorded on FTIR (Shimadzu, Japan) utilizing KBr cartridge ranges from 4000  $\text{cm}^{-1}$  to 400  $\text{cm}^{-1}$  district. The pellets were incubated with 100 mg potassium bromide with 5 mg test pellet at 12,000 psi under vacuum for 3 min. The resulting spectra have been eliminated for pinnacles and any potential changes in the spectra.

Differential scanning calorimetry study was completed on Selgiline unadulterated medication, bearers and improved definition and thermograms were gotten utilizing DSC (Shimadzu, Japan). Precisely gauged Samples (5-10 mg) were set in shut, penetrated, level base aluminum dish. Nitrogen gas was siphoned at stream pace 50 ml/min at steady warming pace of 15°C/min in scope of 50°C - 350°C temperature. The liquefying point, top maxima appearance of any new pinnacles and change fit as a fiddle was noted [1].

### Preparation of Solid Dispersions

The solid dispersion is arranged by utilizing PEG6000 as transporter in the ratios of 1:1, 1:2, 1:3, 1:4 1:5 and 1:6 using acetone as solvent-by-solvent evaporation method. Drug and bearer were weighed and triturated in mortar and pestle for 5 min [4]. This physical mix was then separated in acetone with reliable blending. This dissolvable was dispersed on warming mantle kept up at 45°C  $\pm$  2°C this model was dried in a desiccator for 24hrs over anhydrous Calcium Chloride. Dried mass was rejected, squashed pummeled and went through sifter 60.

**Table 1. Formulae of Solid Dispersions of Selgiline**

Solid Dispersion	Selgiline	PEG6000	Ratio
SS1	50	50	1:1
SS2	50	100	1:2
SS3	50	150	1:3
SS4	50	200	1:4
SS5	50	250	1:5
SS6	50	300	1:6

### In - Vitro Drug Release Study of solid dispersion FS6

In-vitro deterioration examinations promising solid scatterings were performed by USP XXIII Type-II breaking down mechanical get together using at 50 rpm paddle stirrer uses 900 ml pH 6.8 phosphate support at 37  $\pm$  0.5°C as breakdown medium. The alcohol content disintegrating medium (5 mL) was withdrawn during exposure time (2, 4, 6, 8, 10, 15 & 30 min) was quickly replaced with an equal volume crisp medium. Models were separated by 0.22 film channel plate and investigated for content by estimating absorbance at 247 nm. Solution change is fixed from standard change turn and passed on hard fast percent medication isolated. The discharge studies were performed in replicates three.

S. No.	Ingredients (mg)	SL 1	SL2	SL3	SL4	SL5	SL6	SL7	SL8	SL9	SL 10	SL1 1	SL1 2
1	Selegiline AS4 (Concrete scattering counterpart to 50 milligram of untainted remedy)	10	10	10	10	10	10	10	10	10	10	10	10
2	Spray dried Lactose	q.s	q.s	q.s	q.s.	q.s	q.s	q.s	q.s	q.s	q.s	q.s	q.s
3	Mannitol	20	20	20	20	20	20	20	20	20	20	20	20
4	Aloe vera gel	5	10	25	20	–	–	–	–	–	–	–	–
5	Locust bean gum	–	–	–	–	5	10	25	20	–	–	–	–
6	Osimumbasilicu m mucilage	–	–	–	–	–	–	–	–	5	10	25	20
7	Sodium Saccharine	6	6	6	6	6	6	6	6	6	6	6	6
8	Straw berry flavor	6	6	6	6	6	6	6	6	6	6	6	6
9	Magnesium stearate	3	3	3	3	3	3	3	3	3	3	3	3
10	Talc	q.s	q.s	q.s	q.s.	q.s	q.s	q.s	q.s	q.s	q.s	q.s	q.s
	<b>Total Tablet Weight</b>	<b>200</b>	<b>200</b>	<b>200</b>	<b>200</b>	<b>200</b>	<b>200</b>	<b>200</b>	<b>200</b>	<b>200</b>	<b>200</b>	<b>200</b>	<b>200</b>

**Pre-Compression Studies**

The following pre compression studies were conducted for Selgiline and excipient mixture which includes bulk density, tapped density, angle of repose, hausner ratio, Compressibility index. The results were expressed as mean ± S.D in Table 2.

**Preparation of Rapidly Disintegrating Tablets of Selgiline**

**Table 2. Formulae of Rapidly Disintegrating Tablets of Selgiline with Natural Super disintegrants**

**Evaluation of Rapidly Disintegrating Tablets of Selgiline**

The prepared Rapidly Disintegrating Tablets of Selgiline were evaluated for uniformity of weight using 20 tablets [6], hardness (Monsanto tester) using 5 tablets, thickness (verniercaliperse) using 5 tablets, friability (Roche friabilator) using 10 tablets [7], drug content using 10 tablets, in vitro dissolution studies using 3 tablets. The results were expressed as mean ± S.D in Table 2.

**Time for in-vitro dispersal**

A tablet is set at 10 ml pH 6.8 phosphate-supported assay at 37 ± 0.5°C required for complete dispersion [4]

**Consistency of medication content**

For the substance consistency test, ten tablets were estimated beat to fine powder, measure powder unclear from 10 mg of Selgiline was ousted into refined water fluid was sifted (0.22 m film channel plate (Millipore Corporation). The Selgiline substance was coordinated by assessing the absorbance at 247 nm (using UV spectrophotometer, Shimadzu 1700) after being reasonably diluted with purified water.

**Wet time and water absorption ratio (R)**

Tissue paper twice broken into petridish was placed in 5 cm diameter with 6 ml water. A tablet deliberately placed on tissue paper in petri dish. The time required for water to be completely wet at upper surface of tablet is wetting time. The degree of water intake (R) is chosen by going to the condition:

$$R = 100 \times (w_a - w_b) / w_b$$

Tablet loads when  $w_b$  and  $w_a$  water free at any time.

**In vitro Drug Release Study**

The in-vitro dissolution study of tablets of Selgilineby using USP XXIII Type-II dissolution Contraction (Electrolab, Model TDT-06N) using paddle stirrer at 50 rpm at  $37 \pm 0.5^\circ\text{C}$  medium. One tablet was used in each test. Aliquots of separating medium (5 ml) were undoubtedly withdrawn between periods (2, 4, 6, 8, 10, 15 & 30 min) and were quickly separated by an equal volume of new medium. Models were separated by 0.22 film channel plate and checked for content by surveying absorbance at 247 nm.

**Stability studies of optimized formulation FF6**

Considering the excellent concealed stapled glass vases at  $40^\circ\text{C} / 75\% \text{RH}$  over period of 3 months, tablets representing FF6 have been introduced with activated consistency. Over a period of several months, the tablets were clearly checked for any physiological changes that were observed for changes in content and time of in-vitro scattering.

**In-Vivo Pharmacokinetic Studies of Selgiline**

Medication content in the plasma tests was evaluated utilizing the created HPLC technique. A standard chart was plotted to decide the medication by dissecting plasma tests containing various measures of medication. In the present examination blend of phosphate support (pH 3.5): acetonitrile (35:65) arrangement was utilized as the versatile stage.

**Preparation of standard arrangements**

Stock arrangement of 1mg/ml was set up by placing 100mg of medication into volumetric flagon (100 ml) and 5 ml of portable stage was included, sonicated and made the volume with same. From this 10 ml stock course was taken into 100 ml volumetric container volume was made up to make  $100\mu\text{g}/\text{ml}$ . From this 10 ml was taken and volume was made to 100 ml in volumetric container conveys  $10\mu\text{g} / \text{ml}$ . From this 20 ml stock game plan, 100 ml volumetric container volume is made to distribute  $2000\text{ng} / \text{ml}$ . From this, 1, 2, 3-, 4-, 5- and 6-ml stock solutions were taken to produce 200, 400, 600, 800, 1000 and  $1200\text{ng} / \text{ml}$  standard solutions of Selgiline to prepare the standard curve. FLB spiked plasma samples were prepared mixing with 0.5 ml of blank plasma with above standard solutions. Plain plasma is used as the blank.

**Extraction procedure**

One ml of drug solution containing 200, 400, 600, 800, 1000 and  $1200 \text{ng}/\text{ml}$  were combined to a series of test tubes containing 0.5 ml of plasma. Then 0.5 ml acetonitrile was added to each tube and centrifuged at 3000 rpm for 10 min and injected each solution into HPLC to determine the peak area. Then standard curve was plotted between peak area and concentration and calculated slope and correlation coefficient.

**Chromatographic conditions**

The Chromatographic techniques were done on Shimadzu HPLC furnished with C18 segment and UV indicator. Portable stage was separated through  $0.45 \mu\text{m}$  film channel and pushed through the segment Symmetry C18 (X Terra,  $4.6 \times 150 \text{mm}$ )  $5 \mu\text{m}$ , at a stream pace of 1 ml/min and run time was 10 min. Stock arrangement (1mg/ml) of FLB was readied utilizing the versatile stage. The section was equilibrated for 30 min and the dissected at 254 nm utilizing an UV identifier.

**Pharmacokinetic assessment in bunnies**

The institutional creature moral board of trustees (IAEC) of Browns College of Pharmacy, Khammam, concurred the proposed convention of bioavailability investigation of Rapid Disintegrating Tablets of Selgiline. The endorsement was recorded and convention endorsement number was 02/IAEC/CCPER/CPCSEA/2017.

**Subjects and Study Design**

Twelve male light-skinned rabbits weighing  $1.9 \pm 0.2 \text{kg}$  were used for this evaluation. In the present assessment, a cross breed report was adopted in which twelve male pale cleaned individual bunnies were divided into two equal assemblies (Group I and Get-Together II). During prime time, group I ( $n = 6$ ) chose the Power Tablet (50 mg isolate), however FF6 quickly separated the tablet (parcel 50 mg) to Pack II ( $n = 6$ ). Those who fast for life have free access to

water from twelve hours of evaluation. A forced measurement of water is added to surface tablet before being controlled. The mouth stopped for 2 minutes to swear chewing or gulping tablet. Two milliliters of water dose was administered as result. In the second period examination, following 35 days washout period, bunch I got FF6 quickly crumbling tablet and gathering II got control tablet. Blood tests were gathered at 0.125, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h in the wake of dosing from peripheral vein.

**HPLC analysis of Selgiline plasma samples**

The collected blood tests were centrifuged at 4000 rpm for 15 min with serum and transferred to 5 mL downsized scale rotator tubes. 1 mL of 1 ml of acetonitrile on serum was centrifuged at 3000 rpm for 10000 min, and the supernatant fluid was isolated at 40 0 C until the assay test for immobilized solution [8].The HPLC technique has been used to calm serum stabilization. The quantitative validation drug in plasma was performed using the HPLC method by mixing supernatant liquid in HPLC section (circle volume 20 µl and stream rate 1 ml / min). Temperature run time was estimated by checking at 254 nm for 10 minutes using a UV identifier.

**Pharmacokinetic parameters**

Pharmacokinetic parameters were solved using the Drug Scatter Plasma Stabilization Time information. Pharmacokinetic parameters were reviewed from plasma data for each subject using PK Solver (Change 2.0, Baylor College of Medicine, Houston, TX). From Plasma Focus vs. Plasma Focus, Pinnacle Plasma Fixation (Cmax) has the opportunity to connect at apex plasma levels (tmax)

**III. RESULTS AND DISCUSSION**

**Solubility studies of Selgiline**

As Selgiline is a class II drug. It was poorly solubilized in pH6.0 and 6.8 pH buffer with increase in pH range solubility was increased it was easily solubilized in dichloromethane, acetone and methanol.

**Compatibility considers**

Medication similarity studies were done to know any conceivable communication of Selgiline with regular super disintegrants and transporter utilized in plans utilizing fourier transform infra-red Spectroscopy and differential scanning calorimetry

In The FT-IR studies shows that in the Selgiline pure drug, Selgiline and d to pharmacopoeial specifications dehydrated banana powder, optimized solid dispersion (FS6) and optimized rapidly disintegrating tablet (FF6), there is no interaction drug with other excipients.

**Preformulation study**

The results for characterization of blended powder are shown in table...The bulk density of blend varied between 0.303-0.326g/cm<sup>3</sup>. The tapped density was found in the range of 0.341 -0.372g/cm<sup>3</sup>. The powder blends of all formulations had Hausners ratio of less than 1.25 indicating good flow charecteristics, compressibility index less than 25% were considered as free flowing ones i.e.9.1-14.7, the angle of repose below 35 degrees ranges indicates good flow properties i.e.22.3 -27.6. [5]

**Table 3. Pre compression results of formulations FF1-FF12**


Formulae	Angle of Repose (θ)	Bulk Density (gm/cm <sup>3</sup> )	Tapped Density (gm/cm <sup>3</sup> )	HR ratio	Carr's Index
SG1	23.67 ±1.15	0.324±0.008	0.366 ±0.012	1.129	11.4
SG2	22.3 ±1.52	0.326±0.031	0.359 ±0.031	1.101	9.1
SG3	23 ±1.00	0.317±0.010	0.372 ±0.026	1.173	14.7
SG4	27.67±1.52	0.312 ± 0.01	0.355 ±0.010	1.137	12.1

SG5	25.67 ±1.15	0.309±0.0018	0.341 ±0.176	1.103	9.3
SG6	25.33 ±2.08	0.303±0.014	0.349 ± 0.014	1.151	13.1
SG7	23.33 ±1.52	0.318±0.005	0.354 ±0.011	1.113	10.1
SG8	27 ±1.73	0.309±0.006	0.381 ±0.022	1.249	12.8
SG9	27.33 ±1.52	0.305±0.007	0.375 ±0.012	1.229	13.8
SG10	21.33 ±2.08	0.316±0.006	0.377 ± 0.020	1.193	14.2
SG11	22.33 ±2.51	0.305±0.016	0.378 ±0.012	1.239	11.4
SG12	22.67±2.51	0.316±0.006	0.390 ±0.003	1.234	14.9

### Dissolution Studies of Solid Dispersions

When dissolution studies were conducted to solid dispersions and pure drug solid dispersion with 1:5 showed better dissolution rate when compared to other ratios solid dispersion and pure drug. The %CDR of drug was increased with the increase in the concentration of carrier concentration. But the decreased pattern was observed in FS6 solid dispersion due to retardant effect of PEG6000 with excess concentration.

Figure . Dissolution profiles (%CDR) of solid dispersions



### Evaluation of Rapid Disintegrating Tablets of Selgiline


All the tablets were white in colour, round in shape with smooth surface without any defects. The diameter of all the formulations was uniform (7.7-7.8mm). Thickness of all the formulations was found to be within the range of 2.23mm to 2.53mm, all the formulations passed weight variation test as the % weight variation was within the pharmacopoeial limits of ± 7.5%, the hardness is in the range of 3.5-4.5kg/cm<sup>2</sup>, friability was observed less than 1%, the wetting time was rapid in all the formulations the range of 24-33sec which is closely related to inner structure of tablets, in vitro disintegration time is in the range of 21.67-25.25 according to pharmacopoeial specifications banana powder when comes in contact with water they quickly wicks water into the tablet through capillary action to create internal pressure that disintegrate tablet, drug content was found within the range of 98.21-98.64 indicating uniform distribution of drug in all the formulated tablets as per pharmacopoeial specifications




**Table 4. Post compression parameters of Rapidly Disintegrating Tablets of Selgiline**

Formulae	Weight Variation (mg)	Thickness (mm)	Hardness (kg/cm <sup>2</sup> )	Friability (%)	Drug Content	Wetting time(sec)	Water absorption ratio	In-vitro Disintegration (sec)
SG1	450.1±1.619	3.08±0.209	3.13±0.205	0.50±0.020	98.57±0.157	24.00±2.00	36.00±2.00	21.67 ±1.52
SG2	450.3±2.336	3.09±0.314	3.18±0.044	0.51±0.025	98.64±0.332	27.67±1.52	39.00 ±4.00	20.66 ±1.52
SG3	449.1±2.458	3.08±0.265	3.18±0.265	0.46±0.041	98.21±0.340	25.33±2.64	35.00 ±2.00	22.33 ±2.00
SG4	449.3±2.131	2.99±0.288	3.19±0.265	0.48±0.025	99.03±0.468	33.00±4.04	45.00 ±4.00	25.25 ±2.00
SG5	449.7±2.846	3.06±0.189	3.16±0.245	0.48±0.025	98.29±0.605	30.00±1.00	55.30±2.56	23.35 ±2.523
SG6	450.6±2.549	3.00±0.200	3.14±0.313	0.50±0.030	98.92±0.824	35.00±3.00	39.30 ±3.51	26.33 ±1.52
SG7	450.1±2.213	3.04±0.177	3.18±0.252	0.40±0.015	98.94±0.703	20.00±2.00	42.00 ±2.00	32.54 ±1.00
SG8	448.9±1.494	3.05±0.190	3.09±0.223	0.39±0.026	98.13±0.460	22.67±3.50	39.00 ±2.51	30.33 ±2.00
SG9	450.2±1.897	3.02±0.214	3.08±0.229	0.43±0.020	99.54±0.860	25.33±1.52	44.00 ±3.78	34.35 ±2.00
SG10	450.5±1.032	2.98±0.154	3.15±0.246	0.48±0.020	99.22±0.393	21.00±3.00	69.67 ±2.00	36.15 ±2.08
SG11	450.8±1.686	3.00±0.188	3.13±0.226	0.5±0.0170	98.87±0.363	18.00±2.00	71.33 ±4.16	35.65 ±1.52
SG12	450.3±1.414	3.03±0.188	3.2 ±0.249	0.49±0.015	99.95±0.836	22.00±2.00	65.00 ±3.60	38.14 ±2.00

**Figure .Dissolution data of Selgiline rapidly disintegrating tablets containing Mango peel pectin**



**Figure 10. Dissolution data of Selgiline rapidly disintegrating tablets containing orange peel pectin**



Formulations containing Mango peel pectin as super disintegrant shown poor % CDR values when compared with other natural super disintegrants. Among mango peel pectin tablets, formulation FF4 8% showed maximum release of drug with 86% for 30 min. Increased concentration of mango peel pectin may increase the release of the drug with the wicking mechanism. Dehydrated banana powder showed maximum drug release when compared with the other formulations. Among these tablets, formulation FF6 4% showed maximum release of drug with 99% for 30 min. further increase in the concentration of the dehydrated banana powder retarded drug release in the subsequent increased concentrations FF8 6% and FF9 with the release of 70% and 80% respectively. Orange peel pectin as super disintegrant

also shown poor %CDR values when compared with other natural super disintegrants. Among Orange peel pectin tablets, formulation FF12 8% showed maximum release of drug with 83% for 30 min at the concentration 2% drug release was 86% only. These studies suggested that increased concentration of orange peel pectin may increase the release of the drug with the wicking mechanism and burst release mechanism.

Among all the formulations dehydrated banana powder containing formulations FF4 and FF6 shown to better release rate of Selgiline from the dosage form. Thus dehydrated banana powder can use as better natural superdisintegrant in development rapidly disintegrating tablets.

**Stability Studies of Optimized Formulation FF6**

Strength investigations of the plan FF6 of quickly deteriorating tablets were completed to decide the impact of definition added substances on the steadiness of the medication and furthermore to decide the physical dependability of the detailing. The soundness studies were conveyed at 45±1oc for 90 days. Medication content during the examination time frame.

**Table 5. Drug content data of stability formulation (FF6)**

Trial no	1st day	30 <sup>th</sup> day	90 <sup>th</sup> day
I	99.27	94.37	97.39
II	99.27	94.37	97.39
III	99.17	90.23	93.75
Mean(X)	98.55	90.30	93.11
SD	0.298	0.210	0.515

\*Average of three determinations

**In-Vivo Pharmacokinetic Studies**

**Analytical method development: HPLC method**

The HPLC method was developed total run time was set to 10 min and chromatograms of Selgiline appeared at 3.907 min. The chromatograms of blank plasma, pure Selgiline in plasma and Selgiline in mobile phase were shown in Figure 3.1, 3.2 and 3.3. The peak area of Selgiline in mobile phase and plasma was almost similar that indicating.

**Pharmacokinetic evaluation in rabbits**

In this design, pharmacokinetic evaluation was done on rapidly disintegrating tablets FF6 in comparison to control tablet of Selgiline. The *in vitro* data comparison between control and fast dissolving tablets were given in Figure 3.5. The mean Selgiline plasma concentrations of twelve rabbits are shown in Table 3.3 and 3.4 and Figure 3.6.

This part of the study interprets *in vivo* pharmacokinetic investigations of FF6 solid dispersion of Selgiline to verify enhancement dissolution and absorption rate when contrasted to pure drug. The objective *in vivo* pharmacokinetic investigations was to recount the time course of Selgiline concentrations in blood.

From the pharmacokinetic assessment, Selgiline showed up very quickly inside 10 min. in plasma. Increased worth of Ka was observed in FF6 when compared to control tablet that shows the enhanced absorption rate. The t<sub>1/2</sub> was found as 5.13 and 5.18 hr for control and FF6 tablets respectively. The solid dispersion reached peak concentration (C<sub>max</sub>) 11445.46 ng/ml at T<sub>max</sub> of 2 h while it was seen event of control tablet, showing that upgrade of retention in strong scattering example of Selgiline than unadulterated structure. The AUC of control and FF6 tablets of Selgiline were 31495.16 and 43126.52 ng-h/ml correspondingly. These outcomes demonstrated that the FF6 tablet indicated improvement of AUC when contrasted with control tablet of Selgiline. The MRT of control and FF6 quickly breaking down tablets were 5.58 h and 6.00 h individually.

**Table 6. Pharmacokinetic parameters of Selgiline control and FF6 rapidly disintegrating tablets (Mean±S.D, n=12)**

Parameters	Control tablet	FF6 RDTs	t-test at 0.05 LS
ka (1/h)	0.402±0.01	0.486±0.01	Significant
ke (1/h)	0.135±0.01	0.134±0.01	Not Significant
t <sub>1/2</sub> (h)	5.13±1.25	5.18±1.52	Not Significant



T <sub>max</sub> (h)	3.00±0.01	2.00±0.01	Significant
C <sub>max</sub> (ng/ml)	9140.84±614.36	11445.46±149.23	Significant
AUC <sub>0-∞</sub> (ng·h/ml)	31495.16±619.92	43126.52±688.89	Significant
AUMC <sub>0-∞</sub> (ng·h <sup>2</sup> /ml)	175957.60±3046.49	258895.00±3103.94	Significant
MRT (h)	5.58±0.03	6.00±0.03	Significant

From the pharmacokinetic assessment, Selgiline showed up very quickly inside 10 min. in plasma. Increased worth of Ka was observed in FF6 when compared to control tablet that shows the enhanced absorption rate. The t<sub>1/2</sub> was found as 5.13 and 5.18 hr for control and FF6 tablets respectively. The solid dispersion reached peak concentration (C<sub>max</sub>) 11445.46 ng/ml at t<sub>max</sub> of 2 h while it was seen event of control tablet, showing that upgrade of retention in strong scattering example of Selgiline than unadulterated structure. The AUC of control and FF6 tablets of Selgiline were 31495.16 and 43126.52 ng·h/ml correspondingly. These outcomes demonstrated that the FF6 tablet indicated improvement of AUC when contrasted with control tablet of Selgiline. The MRT of control and FF6 quickly breaking down tablets were 5.58 h and 6.00 h individually.

The factual examination of pharmacokinetic parameters of control and FF6 quickly was breaking down critical distinction in the ka among control and FF6 quickly deteriorating tablets, demonstrating that the pace of assimilation is more if there should arise an occurrence of FF6. There was a noteworthy contrast of AUC<sub>0-∞</sub> saw among control and FF6 tablets, which demonstrate the improvement of degree of retention of Selgiline.

The C<sub>max</sub> and T<sub>max</sub> of control and FF6 rapidly disintegrating tablets were significantly different indicating immediate absorption of Selgiline from FF6 tablets. Significant difference of MRT between control and FF6 rapidly disintegrating tablets indicated that difference in time spent by the Selgiline in the body.

All in all, the FF6 quickly breaking down tablets indicated brisk and complete medication discharge inside 30 min. contrasted with control tablets that brought about early t<sub>max</sub> and higher C<sub>max</sub>. As needs be the consequences of the pharmacokinetic study uncovered that the FF6 quickly crumbling tablets containing PEG600 strong scattering improves the bioavailability of inadequately solvent Selgiline.

#### IV. CONCLUSION

The results was obtained sfrom the study, Selgiline solid dispersions were prepared by using PEG 6000 as carrier, Selgiline fast disintegrating tablets were prepared by direct compression method by using optimized Selgiline solid dispersion with mango peel, pectin, dehydrated Banana powder and Orange peel pectin as super disintegrants. All the formulations showed fast disintegrating action. Among all the formulations dehydrated banana powder containing formulations FF5 and FF6 showed less disintegration time and better release rate of Selgiline from the dosage form within thirty minutes. Thus, dehydrated banana powder can be utilized as better regular super disintegrant in the advancement of quickly breaking down tablets when compared to orange peel pectin and mango peel pectin. The conclusion of design and development of fast disintegrating tablets of Selgiline can defeat the inconvenience of poor and less oral bioavailability of Selgiline related with current advanced oral specifying. Further move in direction of this way is required so as help it adequacy by pharmacokinetic and pharmacodynamic thinks about in individuals.

#### REFERENCES

- [1] Yonezawa BY and Sunanda H. Rapidly disintegrating tablets of prepared by the wet compression method: Mechanisam and Optimization. J. Pharm. Sci., 88(1), 1999,10004-10
- [2] Watanbe Y, Koizumi K, Zama Y and Matsumoto Y. New compressed tablet rapidly disintegrating in saliva in the mouth using crystalline cellulose and a disintegrant. Bio. Pharm. Bull., 18(9), 1995, 1308-10.
- [3] Shery J, Arun S and Anroop N. Preparation and evaluation of fast disintegrating effervescent tablets of glibenclamide . Drug Dev Ind Pharm 2009; 35:321-8.
- [4] Rikka L, Eero and Mikko B Perphenazine solid dispersions for orally fast disintegrating tablets: physical stability and formulation. Drug Dev Ind Pharm 2010; 36:601-13.
- [5] Rikka L, Eero and Mikko B Perphenazine Intra orally fast dissolving particles of a poorly soluble drug: preparation and in vitro characterization. Eur J Pharm Biopharm 2009; 73:162-71.

- [6] Banker GS, Anderson NR (1987). Tablets. In: Lachmann L, Liberman HA, Kaing JL, Eds. The theory and practice of industrial pharmacy. 3rd ed. Mumbai: Varghese publishing house, Bombay, p.297-99.
- [7] Indian Pharmacopoeia (1996). The controller of publications: Delhi, Vol. II, p.734-36.
- [8] Manglani UR, Khan IJ, Soni K, Loya P and Saraf MN (2006). Development and validation of HPLC-UV method for the estimation of rebamipide in human plasma, Indian J Pharm.Sci 68(4): 475-478.